Kim Sukyung, Han Song-Yi, Lee Jinyoung, Kim Na-Rae, Lee Bo Ra, Kim Hyunmi, Kwon Mijeoung, Ahn Kangmo, Noh Youngbae, Kim Sang Jong, Lee Phyrim, Kim Dongki, Kim Byung Eui, Kim Jihyun
Department of Pediatrics, Hallym University Dongtan Sacred Heart Hospital, Hallym University School of Medicine, Hwaseong, Korea.
Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Allergy Asthma Immunol Res. 2022 Sep;14(5):549-564. doi: 10.4168/aair.2022.14.5.549.
The beneficial effects of a combination therapy using and galactooligosaccharide (GOS) for the treatment of atopic dermatitis (AD) have not been elucidated.
Gene expressions of interleukin (IL)-4 and IL-13 from peripheral blood mononuclear cells and fecal abundance of . from 12-month-old infants were evaluated. Human primary epidermal keratinocytes (HEKs) and hairless mice were treated with , GOS, -derived extracellular vesicles (BLEVs), dinitrochlorobenzene (DNCB), or a synbiotic mixture of . and GOS. Expression of epidermal barrier proteins and cytokines as well as serum immunoglobulin E (IgE) levels were analyzed in HEKs and mice. Dermatitis scores, transepidermal water loss (TEWL), epidermal thickness, and fecal abundance were evaluated in mice.
Fecal abundance of . was negatively correlated with blood expression in infants. or BLEVs increased expression of filaggrin () and loricrin () in HEKs. . increased the efficacy of GOS to upregulate and expressions in HEKs. Oral administration of GOS increased fecal abundance of . in mice. Oral administration of . attenuated DNCB-induced skin inflammation, abnormal TEWL, AD-like skin, and deficiency of epidermal barrier proteins. Moreover, the combination of and GOS showed greater effects to improve DNCB-induced skin inflammation, abnormal TEWL, AD-like skin, serum IgE levels, over-expression, and the deficiency of epidermal barrier proteins than the administration of alone.
and GOS improve DNCB-induced skin barrier dysfunction and AD-like skin.
使用[未提及物质]和低聚半乳糖（GOS）联合治疗特应性皮炎（AD）的有益效果尚未阐明。
评估了12个月大婴儿外周血单个核细胞中白细胞介素（IL）-4和IL-13的基因表达以及[未提及物质]的粪便丰度。用人源原代表皮角质形成细胞（HEKs）和无毛小鼠分别用[未提及物质]、GOS、[未提及物质]衍生的细胞外囊泡（BLEVs）、二硝基氯苯（DNCB）或[未提及物质]与GOS的合生元混合物进行处理。分析了HEKs和小鼠中表皮屏障蛋白和细胞因子的表达以及血清免疫球蛋白E（IgE）水平。评估了小鼠的皮炎评分、经表皮水分流失（TEWL）、表皮厚度和粪便[未提及物质]丰度。
婴儿粪便中[未提及物质]的丰度与血液中[未提及物质]的表达呈负相关。[未提及物质]或BLEVs增加了HEKs中丝聚蛋白（FLG）和兜甲蛋白（LOR）的表达。[未提及物质]提高了GOS上调HEKs中[未提及物质]和[未提及物质]表达的功效。口服GOS增加了小鼠粪便中[未提及物质]的丰度。口服[未提及物质]减轻了DNCB诱导的皮肤炎症、异常TEWL、类AD皮肤和表皮屏障蛋白缺乏。此外，与单独给予[未提及物质]相比，[未提及物质]和GOS的组合在改善DNCB诱导的皮肤炎症、异常TEWL、类AD皮肤、血清IgE水平、[未提及物质]过表达和表皮屏障蛋白缺乏方面显示出更大的效果。
[未提及物质]和GOS改善了DNCB诱导的皮肤屏障功能障碍和类AD皮肤。
